Supernus Pharmaceuticals of Rockville has sold certain royalty and milestone rights to a treatment for pulmonary arterial hypertension for $30 million to HealthCare Royalty Partners of Stamford, Conn.
The agreement relates to the commercialization of Orenitram Extended-Release Tablets by Supernus’ partner, United Therapeutics of Silver Spring. Supernus will retain full ownership of the royalty rights after a certain threshold has been reached, according to a company news release.